Clinical Laserthermia Systems AB OMXSTO:CLS_B:
Q3 REVENUE AMOUNTED TO SEK 2.8 MILLION
Q3 OPERATING LOSS SEK 7.42 MILLION
Clinical Laserthermia Systems Q3 Revenue SEK 2.8 Mln
Earlier from Clinical Laserthermia Systems Ab Class B
- CLS-sponsored neuro LITT study in patients with malignant brain tumor shows positive results
- Clinical Laserthermia Systems AB: Quarterly Trading Report 2025 Q3
- CLS Raises SEK 20.9 Mln Through Full Subscription Of Warrants
- CLS_B: Record Q2 sales and improved margins drive narrowed losses and strong growth outlook